In my two decades of clinical practice—whether I am consulting with families in the Philippines or working with the vibrant international community in Alicante, Spain—I have often described diabetic retinopathy as a “silent thief.” For years, we have been in a reactive mode, waiting for the eye’s “plumbing” to leak or burst before we start the repair work. By the time a patient notices blurred vision, the thief has already made off with a significant portion of their visual reserve.
But as of March 7, 2026, a groundbreaking discovery from University College London (UCL), published in Science Translational Medicine, has identified the exact moment the thief enters the room. It isn’t a leak; it’s a squeeze. By identifying the protein LRG1 (Leucine-rich alpha-2-glycoprotein 1), we finally have a scientific roadmap to stop vision loss before a single symptom ever appears. This discovery marks a tectonic shift from “damage control” to “structural prevention.”
1. The LRG1 Discovery: Moving from Reaction to Prevention
For decades, the medical world has focused its efforts on a protein called VEGF (Vascular Endothelial Growth Factor). In the late stages of diabetes, VEGF causes abnormal, leaky blood vessels to grow in the retina—a process known as neovascularization. While targeting VEGF has saved the sight of millions, it is fundamentally a “late-stage” fix. It’s like trying to patch a dam that is already crumbling.
The UCL team, however, has found that the damage actually starts much earlier, long before the first leak occurs, with the activation of LRG1.
The “Molecular Squeeze” Mechanism
LRG1 doesn’t cause leaks; it causes constriction. In the earliest stages of diabetes, high blood sugar levels trigger the production of LRG1. This protein targets the pericytes—the specialized contractile cells that wrap around the retina’s tiniest blood vessels (capillaries).
Under the influence of LRG1, these pericytes tighten excessively. Think of it like a boa constrictor slowly tightening its grip on a garden hose. The structural integrity of the vessel is still there, but the “flow” is being choked off.
How Reduced Oxygen Delivery Triggers Damage
This constriction “squeezes” the vessels, physically narrowing the path for blood to flow. This results in retinal ischemia—a significant reduction in oxygen delivery to the light-sensitive tissues at the back of the eye.
Once the retina is starved of oxygen (hypoxia), it enters a state of metabolic distress. In a desperate attempt to breathe, the retina releases VEGF to grow new vessels. But these new vessels are poorly formed, fragile, and prone to bleeding. By identifying LRG1 as the initiator of this “squeeze,” we have found the biological switch that happens before hypoxia even starts.
The Pre-Symptomatic Window: Catching the Thief Early
The most exciting part of this research is that it happens in the “pre-symptomatic” phase. In my practice, I often see patients with clear vision who are already showing elevated LRG1 activity. Their eyes are being “choked” of oxygen long before they realize anything is wrong. By targeting LRG1, we aren’t just cleaning up the mess; we are preventing the “choke” from ever happening.
2. LRG1 vs. VEGF: Why Current Treatments Often Fall Short
Currently, the “gold standard” for treating diabetic eye disease is anti-VEGF injections. While revolutionary, these treatments are inherently limited by their timing and biological target. In my clinic, we often see “non-responders”—patients who undergo monthly, uncomfortable injections only to see their vision continue to decline.
The Limits of Modern Anti-VEGF Injections
Anti-VEGF therapy only works for about 50% of patients. For the other half, the “thief” continues his work unabated. Why? Because VEGF is a response to damage, not the cause of the initial insult. If the LRG1-induced squeeze has already happened and the oxygen supply has been permanently lowered, simply stopping the growth of new vessels doesn’t fix the underlying ischemia. The tissue remains starved, and the “death” of retinal neurons continues.
Why Proactive Intervention is the 2026 Standard
In 2026, the mantra is “Proactive over Reactive.” By the time vision blurs, significant and often irreversible structural damage—such as the loss of photoreceptor cells—has already occurred. Targeting LRG1 allows us to intervene when the blood vessels are still healthy but under stress, preserving the original architecture of the eye.
| Feature | Current VEGF Targeting | New LRG1 Targeting |
| Clinical Stage | Reactive (Post-symptoms) | Proactive (Pre-symptoms) |
| Primary Mechanism | Stops leaks and new growth | Prevents vessel “squeezing” |
| Oxygen Impact | Manages hypoxia response | Maintains oxygen delivery |
| Success Rate | ~50% response rate | Potential for much higher coverage |
| Patient Burden | Frequent eye injections | Targeted molecular therapy |
3. The Clinical Horizon: Senya Therapeutics and the Path to Trials
This isn’t just a lab curiosity; it is a clinical reality in the making. The researchers behind this discovery, including Professors John Greenwood and Stephen Moss, have already positioned this for real-world impact through their UCL spinout, Senya Therapeutics.
From Diabetic Mice to Human Medicine
The transition from mouse models to human application is already well underway. In experiments where LRG1 was shut down in diabetic mice, the early retinal damage simply did not occur. The tiny vessels remained open, oxygen continued to flow, and normal eye function was completely preserved. This gives us immense “intellectual honesty” when speaking to patients: we have seen this work in the biological “blueprint.”
The Role of Senya Therapeutics in Drug Development
Founded in 2019, Senya Therapeutics was created specifically to develop drugs that target LRG1.
- The Therapeutic Agent: A drug designed to block LRG1 has already been developed and is showing high affinity in preclinical models.
- Preclinical Audits: The treatment is currently undergoing final preclinical research to ensure safety and effective delivery to the retina.
- Future Trials: It is slated to move into human clinical trials in the very near future, providing a new option for the millions who don’t respond to current treatments.
4. Dr. Marie’s 2026 Protocol: Protecting Your Vision Today
As your health thought partner, I see the LRG1 discovery as a vital piece of the Systemic Resilience puzzle. While we wait for the first LRG1 inhibitor to hit the clinic, we must focus on the factors that keep your blood vessels “relaxed” and open. We cannot let the “thief” have a free pass while the science catches up.
Managing Metabolic Integrity: The “Full Circle” Approach
High blood sugar is the fuel for LRG1 activity. My approach emphasizes that your eyes are an extension of your metabolic health, not an isolated organ.
- Glycemic Stability: Maintaining an HbA1c below 5.5% is your first line of defense. Spikes in glucose tell your body to produce LRG1, starting the “squeeze.” We use continuous glucose monitors (CGMs) to ensure you aren’t having “silent spikes” after meals that could trigger this protein.
- Vascular Shielding: High blood pressure compounds the constriction caused by LRG1. If the boa constrictor is already squeezing, high blood pressure is like putting weights on the snake. Keeping your BP strictly under 130/80 ensures that even if LRG1 is present, your vessels have the structural integrity to resist the squeeze.
The Importance of Early Screening: Beyond the Eye Chart
Because LRG1 damage happens before symptoms, we can no longer rely on the “can you read the bottom line” test as our cue for help.
- AI-Enhanced Imaging: In 2026, we use AI-powered retinal scans and Optical Coherence Tomography (OCT) to look for subtle changes in vessel diameter—the “early squeeze”—years before traditional exams might catch a leak.
- Infection Audit: As we’ve seen in other 2026 research, systemic inflammation from hidden infections (gut dysbiosis or chronic dental issues) can exacerbate vascular tightening. Clearing the “metabolic noise” allows your retinal vessels to function at peak capacity.
Final Thoughts from Dr. Marie
The realization that diabetic eye disease starts with a “squeeze” rather than a “leak” changes everything. It means we can fire the “molecular debt collector” (LRG1) before it cuts off the oxygen supply to your vision. For the one-third of diabetic adults already showing early signs of retinopathy, this research isn’t just a breakthrough—it’s a beacon of hope.
In my practice, I always tell my patients: your body is a conversation. LRG1 is a “shouting” match between your blood sugar and your vessels. Our goal is to bring that conversation back to a calm, healthy whisper. By combining the latest UCL science with grounded, daily metabolic choices, we are finally capturing the thief before the jewelry is gone.
Let’s look at your metabolic health and protect your vision together.
Dr. Marie Gabrielle A. Laguna, MSc, M.D., FPCP, FDip (Geriatric Rehab, UK) Internal Medicine & Senior Health Specialist



